Inflammation-associated drug resistance and tumor growth in TNBC
Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of hormone receptors and HER2 amplification. This molecular profile limits the effectiveness of targeted therapies, leaving chemotherapy as the mainstay of treatment...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623137/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849222453772943360 |
|---|---|
| author | Arij Fouzat Hassan Hadeel Kheraldine Lama Abujamous Hamda Al-Thawadi Abdelbary Elhissi |
| author_facet | Arij Fouzat Hassan Hadeel Kheraldine Lama Abujamous Hamda Al-Thawadi Abdelbary Elhissi |
| author_sort | Arij Fouzat Hassan |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of hormone receptors and HER2 amplification. This molecular profile limits the effectiveness of targeted therapies, leaving chemotherapy as the mainstay of treatment a strategy often met with limited success due to rapid disease progression and high recurrence rates. Increasing evidence underscores the pivotal role of the tumor microenvironment (TME) in driving TNBC pathogenesis, particularly through chronic inflammation and cytokine dysregulation. Inflammatory cytokines such as TNF-α, TGF-β, IL-6, and IL-10 orchestrate a complex network of cellular interactions that remodel the TME into an immunosuppressive niche. This inflammatory landscape not only promotes tumor cell proliferation and metastasis but also compromises antitumor immune responses and contributes to therapeutic resistance. Recent preclinical and clinical studies have explored the therapeutic potential of targeting cytokine signaling to disrupt this inflammatory axis and overcome resistance. In this review, we critically examine the multifaceted interplay between cytokines, inflammation, and the TME in TNBC, with a focus on mechanisms of resistance. We further evaluate current and emerging therapeutic approaches targeting the inflammatory axis, highlighting both the promise and the complexities of this evolving landscape. |
| format | Article |
| id | doaj-art-d71f3c5be7aa433284dde34c4e0e55f4 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-d71f3c5be7aa433284dde34c4e0e55f42025-08-26T05:27:51ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16231371623137Inflammation-associated drug resistance and tumor growth in TNBCArij Fouzat Hassan0Hadeel Kheraldine1Lama Abujamous2Hamda Al-Thawadi3Abdelbary Elhissi4College of Pharmacy, Department of Pharmaceutical Sciences, QU Health, Qatar University, Doha, QatarCollege of Medicine, Department of Basic Medical Science, QU Health, Qatar University, Doha, QatarCollege of Medicine, Department of Basic Medical Science, QU Health, Qatar University, Doha, QatarCollege of Medicine, Department of Basic Medical Science, QU Health, Qatar University, Doha, QatarCollege of Pharmacy, Department of Pharmaceutical Sciences, QU Health, Qatar University, Doha, QatarTriple-negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer characterized by the absence of hormone receptors and HER2 amplification. This molecular profile limits the effectiveness of targeted therapies, leaving chemotherapy as the mainstay of treatment a strategy often met with limited success due to rapid disease progression and high recurrence rates. Increasing evidence underscores the pivotal role of the tumor microenvironment (TME) in driving TNBC pathogenesis, particularly through chronic inflammation and cytokine dysregulation. Inflammatory cytokines such as TNF-α, TGF-β, IL-6, and IL-10 orchestrate a complex network of cellular interactions that remodel the TME into an immunosuppressive niche. This inflammatory landscape not only promotes tumor cell proliferation and metastasis but also compromises antitumor immune responses and contributes to therapeutic resistance. Recent preclinical and clinical studies have explored the therapeutic potential of targeting cytokine signaling to disrupt this inflammatory axis and overcome resistance. In this review, we critically examine the multifaceted interplay between cytokines, inflammation, and the TME in TNBC, with a focus on mechanisms of resistance. We further evaluate current and emerging therapeutic approaches targeting the inflammatory axis, highlighting both the promise and the complexities of this evolving landscape.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623137/fulltriple-negative breast cancer (TNBC)tumor microenvironment (TME)inflammationcytokinesdrug resistance |
| spellingShingle | Arij Fouzat Hassan Hadeel Kheraldine Lama Abujamous Hamda Al-Thawadi Abdelbary Elhissi Inflammation-associated drug resistance and tumor growth in TNBC Frontiers in Immunology triple-negative breast cancer (TNBC) tumor microenvironment (TME) inflammation cytokines drug resistance |
| title | Inflammation-associated drug resistance and tumor growth in TNBC |
| title_full | Inflammation-associated drug resistance and tumor growth in TNBC |
| title_fullStr | Inflammation-associated drug resistance and tumor growth in TNBC |
| title_full_unstemmed | Inflammation-associated drug resistance and tumor growth in TNBC |
| title_short | Inflammation-associated drug resistance and tumor growth in TNBC |
| title_sort | inflammation associated drug resistance and tumor growth in tnbc |
| topic | triple-negative breast cancer (TNBC) tumor microenvironment (TME) inflammation cytokines drug resistance |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623137/full |
| work_keys_str_mv | AT arijfouzathassan inflammationassociateddrugresistanceandtumorgrowthintnbc AT hadeelkheraldine inflammationassociateddrugresistanceandtumorgrowthintnbc AT lamaabujamous inflammationassociateddrugresistanceandtumorgrowthintnbc AT hamdaalthawadi inflammationassociateddrugresistanceandtumorgrowthintnbc AT abdelbaryelhissi inflammationassociateddrugresistanceandtumorgrowthintnbc |